Artelo Biosciences (NASDAQ:ARTL) Posts Quarterly Earnings Results, Beats Estimates By $3.83 EPS

Artelo Biosciences (NASDAQ:ARTL) released its quarterly earnings results on Thursday. The company reported ($3.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.02) by $3.83, FiscalAI reports.

Artelo Biosciences Trading Up 0.2%

NASDAQ ARTL traded up $0.01 during trading hours on Friday, reaching $2.10. 6,851 shares of the company traded hands, compared to its average volume of 287,058. Artelo Biosciences has a 12 month low of $1.91 and a 12 month high of $179.19. The stock has a market capitalization of $1.16 million, a PE ratio of -0.01 and a beta of 0.01. The company has a 50 day moving average of $3.55 and a two-hundred day moving average of $19.95.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, September 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Artelo Biosciences presently has an average rating of “Reduce”.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas. Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia.